RESTIT : Evaluation of Resorbable Osteosynthesis Devices Versus Titanium in Maxillofacial Surgery

NCT ID: NCT00240669

Last Updated: 2007-04-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

308 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary objective : To evaluate the quality of fractures setting and osteotomy of the facial massif osteosynthesised with resorbable device PLLA/PGA compared with usual Titanium plates.

Secondary objective :

* To evaluate the resorbable device ergonomy versus Titanium.
* To evaluate the clinical tolerance of resorbable device versus Titanium.

Hypothesis :

Osteosynthesis with resorbable device demonstrates a non inferiority success probability regarding the success observed in osteosynthesis with Titanium, with a less important probability of re-operation.

Study duration : 14 months for each patient.

Study treatment :

* Group I : Resorbable device PLLA/PGA.
* Group II : Titanium device.

Study visits :

\- Screening visit - Baseline with randomization and surgery - Day1 - Day 21 - Day 45(Traumatology)/Day 90 (orthognatic) - Month 6,12 and 14.

Randomization : Stratification by centres, mono or bimaxillar surgery and traumatologic or orthognatic criteria.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Maxillo-Facial Surgery

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Maxillo facial surgery, osteosynthesis, resorbable device

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Resorbable device PLLA/PGA

Intervention Type DEVICE

Titanium device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18\<Age\<50.
* One or more fractures of facial massif requiring a surgical setting with osteosynthesis plates.
* One or more osteotomy of facial massif requiring a surgical setting with osteosynthesis plates.
* Orally and written informed patient. Patient willing to participate the study.
* Signed informed consent.

Exclusion Criteria

* Any previous surgery at the same operative site.
* Patient suffering from chronic affection which could interfere with bone consolidation.
* Corticotherapy, immunosuppressive or anticonvulsant treatment or long term antibiotherapy.
* Nursing or pregnant female.
* Patient with a high risk of non compliance to sudy visits.
* Unconscious patient.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pierre BOULETREAU, MD

Role: PRINCIPAL_INVESTIGATOR

Hospices Civile de Lyon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pierre Bouletreau

Lyon, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pierre BOULETREAU, MD

Role: CONTACT

Phone: 33 4 78 86 19 36

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pierre BOULETREAU, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2004.366

Identifier Type: -

Identifier Source: org_study_id